• Total revenue down 69.53% due to decreased product sales
• Net loss decreased by 14.73% driven by lower fair value changes
• Significant investments in sales, marketing, and R&D to support growth

Imricor Medical Systems Inc reported total revenue of $292,309 for the year ended 31 December 2025, a 69.53% decrease from the prior corresponding period. This was largely driven by decreased product sales, particularly of third-party equipment and the company's consumable devices. Consumable device sales were impacted by European customer sites enrolling patients in the company's VISABL-AFL clinical trial, which are non-revenue generating. The net loss for the year decreased to $25,318,562, down 14.73% from the prior year, primarily due to a smaller charge for the change in fair value of the convertible note and derivative liability, partially offset by a foreign currency exchange gain. When adjusting for these items, the net loss was 33% higher compared to the prior year. During 2025, the company made strategic investments in sales and marketing capabilities, resulting in increased personnel costs as it expanded the European field sales team to support the launch of new products. The company also began initial hiring of U.S. sales and marketing staff to support commercial activities following FDA approval. Growth in research and development investment was driven by the hiring of personnel to support ongoing efforts toward FDA approval in the United States. The company ended the year with total liquidity, defined as cash, cash equivalents, and marketable securities, of $40,779,957.